Literature DB >> 22539458

Hepatic lipase activity is increased in non-alcoholic fatty liver disease beyond insulin resistance.

V Miksztowicz1, D Lucero, V Zago, L Cacciagiú, G Lopez, E Gonzalez Ballerga, J Sordá, E Fassio, L Schreier, G Berg.   

Abstract

BACKGROUND AND
OBJECTIVE: Hepatic lipase is a lipolytic enzyme mostly synthesized and localized at the surface of liver sinusoidal capillaries, which hydrolyses triglycerides and phospholipids of intermediate density, large low density (LDL) and high density lipoproteins. Hepatic lipase activity is increased in insulin resistant states. Non-alcoholic fatty liver disease (NAFLD) is characterized by insulin resistance. However, at present, no data are available regarding the behaviour of hepatic lipase with regard to the degree of hepatic steatosis. Our aim was to evaluate hepatic lipase activity in NAFLD patients and its relationship to the severity of hepatic steatosis. DESIGN AND PATIENTS: We studied 48 patients with NAFLD (diagnosed by ultrasonography and confirmed by liver biopsy) and 30 controls. Steatosis was semi-quantitatively assessed and considered as mild or grade 1, moderate or grade 2 and severe or grade 3. MEASUREMENTS: hepatic lipase activity, lipid and lipoprotein profile (including intermediate density lipoproteins and dense LDL), adiponectin, insulin, glucose and high sensitivity C-reactive protein were measured. Homeostasis model assessment for insulin resistance (HOMA) index was calculated.
RESULTS: Patients with hepatic steatosis presented with higher hepatic lipase activity, HOMA and dense LDL and lower levels of adiponectin, high density lipoproteins, cholesterol and apoA-I. Hepatic lipase activity positively correlated significantly with the severity of hepatic steatosis. Hepatic lipase correlated with a more atherogenic profile and persisted higher in patients even after corrected for age, gender, body mass index, HOMA and adiponectin.
CONCLUSION: The higher hepatic lipase activity in NAFLD patients contributes to a more atherogenic profile linked to increased cardiovascular risk, beyond the insulin resistance and the reduction in adiponectin.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22539458     DOI: 10.1002/dmrr.2312

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  11 in total

Review 1.  Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.

Authors:  David E Cohen; Edward A Fisher
Journal:  Semin Liver Dis       Date:  2013-11-12       Impact factor: 6.115

2.  Role of SN1 lipases on plasma lipids in metabolic syndrome and obesity.

Authors:  Verónica Miksztowicz; Laura Schreier; Mary McCoy; Diego Lucero; Eduardo Fassio; Jeffrey Billheimer; Daniel J Rader; Gabriela Berg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-01-23       Impact factor: 8.311

3.  A new enzyme-linked immunosorbent assay system for human serum hepatic triglyceride lipase.

Authors:  Kazuya Miyashita; Katsuyuki Nakajima; Isamu Fukamachi; Yuji Muraba; Takafumi Koga; Yohnosuke Shimomura; Tetsuyo Machida; Masami Murakami; Junji Kobayashi
Journal:  J Lipid Res       Date:  2017-06-20       Impact factor: 5.922

4.  Correlation of Body Mass Index and Serum Parameters With Ultrasonographic Grade of Fatty Change in Non-alcoholic Fatty Liver Disease.

Authors:  Ghobad Abangah; Atefeh Yousefi; Rouhangiz Asadollahi; Yousef Veisani; Paria Rahimifar; Sajjad Alizadeh
Journal:  Iran Red Crescent Med J       Date:  2014-01-05       Impact factor: 0.611

5.  LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study.

Authors:  Kento Imajo; Hideyuki Hyogo; Masato Yoneda; Yasushi Honda; Takaomi Kessoku; Wataru Tomeno; Yuji Ogawa; Masataka Taguri; Hironori Mawatari; Yuichi Nozaki; Koji Fujita; Hiroyuki Kirikoshi; Satoru Saito; Yoshio Sumida; Masafumi Ono; Koichiro Wada; Atsushi Nakajima; Yuichiro Eguchi
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

6.  Insulin Clearance Is Associated with Hepatic Lipase Activity and Lipid and Adiposity Traits in Mexican Americans.

Authors:  Artak Labadzhyan; Jinrui Cui; Miklós Péterfy; Xiuqing Guo; Yii-Der I Chen; Willa A Hsueh; Jerome I Rotter; Mark O Goodarzi
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

7.  The Proline 7 Substitution in the Preproneuropeptide Y Is Associated with Higher Hepatic Lipase Activity In Vivo.

Authors:  Stephan Schiekofer; Marcus E Kleber; Winfried Maerz; Franz M Rasche; Jochen G Schneider
Journal:  Int J Endocrinol       Date:  2017-05-30       Impact factor: 3.257

8.  Inverse Relationship between Hepatic Steatosis and Alanine Aminotransferase with Sex Hormone-Binding Globulin in Men.

Authors:  In Ho Seo; Hyung Bin Lee; Shinhye Kim; Yong Jae Lee; Dong Hyuk Jung
Journal:  Yonsei Med J       Date:  2017-07       Impact factor: 2.759

Review 9.  How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?

Authors:  Yana Geng; Klaas Nico Faber; Vincent E de Meijer; Hans Blokzijl; Han Moshage
Journal:  Hepatol Int       Date:  2021-02-06       Impact factor: 6.047

10.  Human hepatic lipase overexpression in mice induces hepatic steatosis and obesity through promoting hepatic lipogenesis and white adipose tissue lipolysis and fatty acid uptake.

Authors:  Lídia Cedó; David Santos; Núria Roglans; Josep Julve; Victor Pallarès; Andrea Rivas-Urbina; Vicenta Llorente-Cortes; Joan Carles Laguna; Francisco Blanco-Vaca; Joan Carles Escolà-Gil
Journal:  PLoS One       Date:  2017-12-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.